Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology

Archive ouverte

Deligne, Clémence | Tourbez, Arthur | Bénard, Flavie | Meyer, Swann | Curt, Alexis | Gianesello, Matteo | Hamadou, Maud | Clavier, Léna | Coquet, Claire | Bocquet, Charlotte | Tomine, Julia | Diot, Thomas | Paraqindes, Hermes | Marcel, Virginie | Berthelot, Clément | Engel, Justine | Rochet, Isabelle | Barritault, Marc | Savary, Clara | Gadot, Nicolas | Attignon, Valéry | Carrere, Marjorie | Billaud, Marc | Dutour, Aurélie | Cordier-Bussat, Martine | Beuriat, Pierre-Aurélien | Szathmari, Alexandru | Di Rocco, Federico | Blay, Jean-Yves | Tiberi, Luca | Vasiljevic, Alexandre | Meyronet, David | Castets, Marie | Leblond, Pierre | Broutier, Laura

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Abstract Background Brain tumors are the deadliest solid tumors in children and adolescents. Most of these tumors are glial in origin and exhibit strong heterogeneity, hampering the development of effective therapeutic strategies. In the past decades, patient-derived tumor organoids (PDT-O) have emerged as powerful tools for modeling tumoral cell diversity and dynamics, and they could then help define new therapeutic options for pediatric brain tumors. Methods Through an integrative approach based on our expertise and a careful review of the literature about glioblastoma 3D primary cultures, we set up a standardized methodological pipeline for the establishment, characterization, and biobanking of PDT-O through direct 3D in vitro culture of the deadliest pediatric glial brain tumors. To assess PDT-O fidelity and validate their preclinical relevance, we performed comprehensive histological, molecular, and drug-response analyses. Results Our methodological pipeline allowed the rapid and efficient generation of PDT-O recapitulating their parental tumor features, including intratumoral heterogeneity, even after several passages and cryopreservation/revival as 3D cultures. Moreover, we successfully performed preclinical test responses on these PDT-O to standard-of-care therapies and new therapeutic options. Finally, we identified ONC201 as a selective drug for pediatric glial tumor types not restricted to H3K27-altered glial tumors, as well as combination strategies to increase the therapeutic response to ONC201. Conclusions Hence, we describe a fast and robust process to biobank PDT-O for pediatric glial brain tumors. These PDT-O models have the potential for patient-specific modeling even after long-term expansion in vitro, and we established the proof-of-concept of their usefulness to support powerful preclinical studies.

Consulter en ligne

Suggestions

Du même auteur

Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers

Archive ouverte | Savary, Clara | CCSD

International audience. Highlights d Relapsed rhabdomyosarcoma (RMS) 3D organoids can be derived from needle biopsies d RMS 3D organoids finely preserve inter-and intra-tumor heterogeneity d Transcriptomic approach ...

BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas

Archive ouverte | Huchede, Paul | CCSD

International audience. Pediatric diffuse midline gliomas (pDMG) are an aggressive type of childhood cancer with a fatal outcome. Their major epigenetic determinism has become clear, notably with the identification ...

The TLR3 L412F polymorphism prevents TLR3-mediated tumor cell death induction in pediatric sarcomas

Archive ouverte | Bisaccia, Joseph | CCSD

International audience. Toll-like receptor 3 (TLR3) is a pattern recognition receptor mainly known for its role in innate immune response to infection. Indeed, binding of double-stranded RNA (dsRNA) to TLR3 triggers...

Chargement des enrichissements...